# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evercore ISI Group analyst Vijay Kumar maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price targe...
- Reuters
WuXi AppTec employees collaborated with China's PLA on altitude sickness drugs, raising national security concerns in the U...
RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and maintains $125 price target.